Alkermes (ALKS) Cash from Financing Activities (2010 - 2026)
Alkermes (ALKS) reported Cash from Financing Activities of $1.5 billion for Q1 2026, up 197292.1% year-over-year from N/an in Q1 2025, and up 13412.82% quarter-over-quarter from $10.9 million in Q4 2025.
Alkermes (ALKS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Cash from Financing Activities data on file, last reported at $1.5 billion in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $1.5 billion, up 197292.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 412.53% YoY), and the FY2025 annual result was $12.4 million, up 102.51% from the prior year.
- Cash from Financing Activities rose to $1.5 billion in Q1 2026 per ALKS's latest filing, from $10.9 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $1.5 billion in Q1 2026 and troughed at -$281.7 million in Q4 2024.
- A 5-year average of $41.3 million and a median of -$212000.0 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities slumped 101928.41% in 2023, then jumped 197292.1% in 2026.
- A 5-year view of Cash from Financing Activities shows it stood at -$271000.0 in 2022, then tumbled by 101928.41% to -$276.5 million in 2023, then retreated by 1.87% to -$281.7 million in 2024, then soared by 103.87% to $10.9 million in 2025, then jumped by 13412.82% to $1.5 billion in 2026.
- Business Quant data shows ALKS's Cash from Financing Activities at $1.5 billion in Q1 2026, $10.9 million in Q4 2025, and $315000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn | -18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.47 Bn |
| Mar 31, 2026 | 1.47 Bn |
| Dec 31, 2025 | 10.91 Mn |
| Dec 31, 2025 | 10.91 Mn |
| Sep 30, 2025 | 315,000.00 |
| Sep 30, 2025 | 315,000.00 |
| Jun 30, 2025 | 405,000.00 |
| Jun 30, 2025 | 405,000.00 |
| Mar 31, 2025 | 747,000.00 |
| Mar 31, 2025 | 747,000.00 |
| Dec 31, 2024 | -281.67 Mn |
| Dec 31, 2024 | -281.67 Mn |
| Sep 30, 2024 | -111.11 Mn |
| Sep 30, 2024 | -111.11 Mn |
| Jun 30, 2024 | -83.48 Mn |
| Jun 30, 2024 | -83.48 Mn |
| Mar 31, 2024 | -17.87 Mn |
| Mar 31, 2024 | -17.87 Mn |
| Dec 31, 2023 | -276.50 Mn |
| Dec 31, 2023 | -276.50 Mn |